AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2390518 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluorescein (25 mg/kg body weight)
Number of subjects: 0
Study 2390518 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluorescein (capsules)
Number of subjects: 0
Study 2390518 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fluorescein
Number of subjects: 0
Study 6947987 — intervention group
Group type: COMPARATOR
Intervention: 0.2% chlorhexidine gluconate mouthrinse
Number of subjects: 0
Study 6947987 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.035% alexidine mouthrinse
Number of subjects: 0
Study 31122893 — intervention group
Group type: EXPERIMENTAL
Intervention: PRM-151
Number of subjects: 111
Study 31122893 — intervention group
Group type: EXPERIMENTAL
Intervention: PRM-151 (crossover from placebo)
Number of subjects: 111
Study 28703608 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic patient feedback using the Partners for Change Outcome Management System (PCOMS)
Number of subjects: 2247
Study 26643821 — intervention group
Group type: EXPERIMENTAL
Intervention: Apical lead positioning
Number of subjects: 98
Study 26643821 — intervention group
Group type: COMPARATOR
Intervention: Midseptal lead positioning
Number of subjects: 98
Study 24587764 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapubic aspiration (SPA)
Number of subjects: 0
Study 24587764 — intervention group
Group type: COMPARATOR
Intervention: Transurethral catheterization (TUC)
Number of subjects: 0
Study 22233415 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin alpha-1 1.6 mg SC twice weekly for 48 weeks
Number of subjects: 552
Study 22233415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 552
Study 22233415 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin alpha-1 with standard of care
Number of subjects: 552
Study 22233415 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (peginterferon alfa-2a 180 mg/week with RBV 800-1200 mg/daily)
Number of subjects: 552
Study 20123365 — intervention group
Group type: EXPERIMENTAL
Intervention: Cone-beam computed tomography (CBCT)
Number of subjects: 28
Study 20123365 — intervention group
Group type: COMPARATOR
Intervention: Multislice computed tomography (MSCT)
Number of subjects: 28
Study 17570054 — intervention group
Group type: EXPERIMENTAL
Intervention: Habit reversal program with a pager to check tooth position and masticatory muscle tension, paging approximately once every 2 hours during the day for 4 weeks.
Number of subjects: 8
Study 17570054 — intervention group
Group type: COMPARATOR
Intervention: Behaviorally-modified dental intervention (splint therapy) using an interocclusal appliance worn up to 20 hours per day for 4 weeks.
Number of subjects: 8
Study 16262733 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily self-administered 6-month regimen of rifampicin and isoniazid
Number of subjects: 268
Study 16262733 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly, directly observed 6-month regimen of rifampicin and isoniazid plus pyrazinamide for the first 2 months
Number of subjects: 268
Study 12006901 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 123
Study 12006901 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 123
Study 12006901 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 123
Study 12006901 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 123
Study 12006901 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 123
Study 10440436 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin/sulbactam (150 to 300 mg/kg/day in divided doses every 6 hours)
Number of subjects: 98
Study 10440436 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime (50 to 100 mg/kg/day in divided doses every 6 or 8 hours)
Number of subjects: 98
Study 7758054 — intervention group
Group type: EXPERIMENTAL
Intervention: NIF CC 30 mg daily with food
Number of subjects: 228
Study 7758054 — intervention group
Group type: EXPERIMENTAL
Intervention: NIF GITS 30 mg daily with food
Number of subjects: 228
Study 7758054 — intervention group
Group type: EXPERIMENTAL
Intervention: NIF CC 60 mg daily
Number of subjects: 228
Study 7758054 — intervention group
Group type: EXPERIMENTAL
Intervention: NIF GITS 60 mg daily
Number of subjects: 228
Study 7758054 — intervention group
Group type: EXPERIMENTAL
Intervention: NIF CC
Number of subjects: 228
Study 7758054 — intervention group
Group type: COMPARATOR
Intervention: NIF GITS
Number of subjects: 228
Study 31464592 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls Active programme (intervention)
Number of subjects: 10
Study 31464592 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and resources of Girls Active programme (intervention)
Number of subjects: 10
Study 31464592 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors affecting implementation (intervention)
Number of subjects: 10
Study 31464592 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback forms and attendance records (intervention)
Number of subjects: 10
Study 31464592 — intervention group
Group type: EXPERIMENTAL
Intervention: Exit survey (intervention)
Number of subjects: 10
Study 31464592 — intervention group
Group type: COMPARATOR
Intervention: School environment questionnaire (intervention and control)
Number of subjects: 10
Study 28905108 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/day, days 1-21)
Number of subjects: 37
Study 28905108 — intervention group
Group type: COMPARATOR
Intervention: S-1 (80-120 mg/day, days 1-14)
Number of subjects: 37
Study 26738328 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Tamsulosin at 0.2 mg qd plus Xipayimaizipizi at 0.5 g tid)
Number of subjects: 60
Study 26738328 — intervention group
Group type: COMPARATOR
Intervention: Control (Tamsulosin at 0.2 mg qd)
Number of subjects: 60
Study 26738328 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 60
Study 26738328 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 23427848 — intervention group
Group type: EXPERIMENTAL
Intervention: Affiliation arousal
Number of subjects: 0
Study 23427848 — intervention group
Group type: EXPERIMENTAL
Intervention: Social exclusion
Number of subjects: 0
Study 23427848 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 21224838 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole MR 30 mg
Number of subjects: 305
Study 21224838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study 18950736 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly oral ibandronate (150 mg)
Number of subjects: 160
Study 18950736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 17299073 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine
Number of subjects: 100
Study 17299073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 15203552 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg every other day orally
Number of subjects: 27
Study 11593074 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine, Clomipramine, Citalopram, Paroxetine (standardized treatment over 12 weeks)
Number of subjects: 159
Study 11593074 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (non-responders)
Number of subjects: 159
Study 9390612 — intervention group
Group type: EXPERIMENTAL
Intervention: UpsherScope (Group US)
Number of subjects: 300
Study 9390612 — intervention group
Group type: COMPARATOR
Intervention: Direct Laryngoscopy (Group DL)
Number of subjects: 300
Study 7947206 — intervention group
Group type: EXPERIMENTAL
Intervention: Desonide (Locapred)
Number of subjects: 40
Study 7947206 — intervention group
Group type: COMPARATOR
Intervention: Excipient
Number of subjects: 40
Study 3630963 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight bulimic patients
Number of subjects: 0
Study 3630963 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorectic-restrictor and anorectic-bulimic patients
Number of subjects: 0
Study 3630963 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight regain
Number of subjects: 0
Study 29030140 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 5699
Study 29030140 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 5699
Study 27612583 — intervention group
Group type: EXPERIMENTAL
Intervention: HD13 trial (early-stage favourable)
Number of subjects: 4215
Study 27612583 — intervention group
Group type: EXPERIMENTAL
Intervention: HD14 trial (early-stage unfavourable)
Number of subjects: 4215
Study 27612583 — intervention group
Group type: EXPERIMENTAL
Intervention: HD15 trial (advanced-stage)
Number of subjects: 4215
Study 25671925 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Morphine 0.1mg/kg and Intravenous lidocaine 1.5 mg/kg
Number of subjects: 60
Study 25671925 — intervention group
Group type: COMPARATOR
Intervention: Intravenous Morphine 0.1mg/kg and lidocaine spray 1.5 mg/kg
Number of subjects: 60
Study 24231018 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-protein diet (HP: 32% protein; 12.2 mg/day iron; 11.7 mg/day zinc)
Number of subjects: 36
Study 24231018 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-protein diet (HP) with >=10% weight loss
Number of subjects: 36
Study 24231018 — intervention group
Group type: COMPARATOR
Intervention: Lower-protein diet (LP: 20%; 9.9 mg/day iron; 7.6 mg/day zinc) with >=10% weight loss
Number of subjects: 36
Study 20121898 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (3 g three times daily)
Number of subjects: 30
Study 20121898 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 g three times daily)
Number of subjects: 30
Study 19216279 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-supported removable partial denture (ISRPD)
Number of subjects: 5
Study 19216279 — intervention group
Group type: COMPARATOR
Intervention: Conventional removable partial denture (CRPD)
Number of subjects: 5
Study 15983759 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin
Number of subjects: 185
Study 15983759 — intervention group
Group type: COMPARATOR
Intervention: Noncolistin
Number of subjects: 185
Study 12668989 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid solution (75 g)
Number of subjects: 48
Study 12668989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 10376778 — intervention group
Group type: EXPERIMENTAL
Intervention: Pistachio nuts (20% of daily caloric intake)
Number of subjects: 10
Study 8911573 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDS education and risk reduction training
Number of subjects: 27
Study 8911573 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 27
Study 2068695 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 1600 microgram/day
Number of subjects: 24
Study 2068695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 6370438 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% diflorasone diacetate ointment in a vehicle of propylene glycol (PG)
Number of subjects: 24
Study 6370438 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% fluocinonide ointment
Number of subjects: 24
Study 6370438 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol propionate ointment
Number of subjects: 24
Study 6370438 — intervention group
Group type: COMPARATOR
Intervention: Vehicle for diflorasone diacetate PG
Number of subjects: 24
Study 30987643 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intoxication (measured by Blood Alcohol Concentration - BAC)
Number of subjects: 1410
Study 30987643 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported risky alcohol habits
Number of subjects: 1410
Study 30987643 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for restrictive alcohol policies
Number of subjects: 1410
Study 30987643 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender differences in BAC and drinking habits
Number of subjects: 1410
Study 29929610 — intervention group
Group type: EXPERIMENTAL
Intervention: Double volume saline (2 ml/kg/h for 12 h before and after the procedure)
Number of subjects: 303
Study 29929610 — intervention group
Group type: COMPARATOR
Intervention: Standard volume saline (1 ml/kg/h for 12 h before and after the procedure)
Number of subjects: 303
Study 27472964 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy (CRT)
Number of subjects: 60
Study 27472964 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 60
Study 24528614 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rapamycin plus bare-metal stent (OR)
Number of subjects: 200
Study 24528614 — intervention group
Group type: COMPARATOR
Intervention: Drug-eluting stent (DES)
Number of subjects: 200
Study 22950365 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional authorship (n = 35)
Number of subjects: 67
Study 22950365 — intervention group
Group type: COMPARATOR
Intervention: Ghostwritten paper (n = 32)
Number of subjects: 67
Study 20232758 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral simvastatin (40 mg/d) plus topical betamethasone (50% in petrolatum) for 8 weeks
Number of subjects: 30
Study 20232758 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo plus topical betamethasone (50% in petrolatum) for 8 weeks
Number of subjects: 30
Study 17683108 — intervention group
Group type: EXPERIMENTAL
Intervention: Sober condition
Number of subjects: 1232
Study 17683108 — intervention group
Group type: EXPERIMENTAL
Intervention: Intoxicated condition
Number of subjects: 1232
Study 15050090 — intervention group
Group type: EXPERIMENTAL
Intervention: Family cognitive‐behavioral therapy
Number of subjects: 182
Study 15050090 — intervention group
Group type: COMPARATOR
Intervention: Individual cognitive‐behavioral therapy
Number of subjects: 182
Study 11150449 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine admission after isolated mild closed head injury
Number of subjects: 1033
Study 11150449 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned)
Number of subjects: 1033
Study 9734756 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation 1.5 mg/kg for 15 days
Number of subjects: 141
Study 9734756 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation 6.0 mg/kg for 15 days
Number of subjects: 141
Study 9734756 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation 6.0 mg/kg for 30 days
Number of subjects: 141
Study 7520659 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) treatment
Number of subjects: 0
Study 2648105 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 45
Study 2648105 — intervention group
Group type: COMPARATOR
Intervention: Suprofen
Number of subjects: 45
Study 2648105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 4919024 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine 100 mg twice a day
Number of subjects: 391
Study 4919024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 391
Study 31623324 — intervention group
Group type: EXPERIMENTAL
Intervention: Photo story booklet regarding doctor‐patient communication
Number of subjects: 120
Study 31623324 — intervention group
Group type: COMPARATOR
Intervention: Non‐narrative brochure
Number of subjects: 120
Study 31623324 — intervention group
Group type: EXPERIMENTAL
Intervention: Photo story booklet (from interview study)
Number of subjects: 120
Study 28403850 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg once daily
Number of subjects: 110
Study 28403850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 25218264 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressurised irrigation
Number of subjects: 256
Study 25234525 — intervention group
Group type: EXPERIMENTAL
Intervention: Papilla base incision (PBI)
Number of subjects: 24
Study 25234525 — intervention group
Group type: COMPARATOR
Intervention: Intrasulcular flap (IS)
Number of subjects: 24
Study 22354598 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 20 mg three times daily
Number of subjects: 277
Study 22354598 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 40 mg three times daily
Number of subjects: 277
Study 22354598 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 80 mg three times daily
Number of subjects: 277
Study 22354598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 277
Study 19124036 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichoptic masking
Number of subjects: 0
Study 19124036 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual differences in dichoptic masking and binocular rivalry measures
Number of subjects: 0
Study 17509689 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal pegaptanib sodium (1 mg or 3 mg) every 6 weeks for 54 weeks
Number of subjects: 147
Study 17509689 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 147
Study 15632883 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 0
Study 15632883 — intervention group
Group type: COMPARATOR
Intervention: Coumadin plus aspirin
Number of subjects: 0
Study 15632883 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel plus aspirin
Number of subjects: 0
Study 15632883 — intervention group
Group type: COMPARATOR
Intervention: Cilostazol plus aspirin
Number of subjects: 0
Study 11447356 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training (drop jumps from 50 cm)
Number of subjects: 0
Study 11447356 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric training (drop jumps from 100 cm)
Number of subjects: 0
Study 11447356 — intervention group
Group type: COMPARATOR
Intervention: Control group (regular midseason training)
Number of subjects: 0
Study 9820393 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported rectal bleeding
Number of subjects: 1643
Study 9820393 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported rectal bleeding (blood on wiping)
Number of subjects: 1643
Study 9820393 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported rectal bleeding (blood coating stools)
Number of subjects: 1643
Study 9820393 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported rectal bleeding (dark blood mixed in stools)
Number of subjects: 1643
Study 9820393 — intervention group
Group type: COMPARATOR
Intervention: Age group comparison
Number of subjects: 1643
Study 9820393 — intervention group
Group type: EXPERIMENTAL
Intervention: Constipation as a predictor
Number of subjects: 1643
Study 9820393 — intervention group
Group type: EXPERIMENTAL
Intervention: Diarrhea as a predictor
Number of subjects: 1643
Study 9820393 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care seeking behavior
Number of subjects: 1643
Study 9820393 — intervention group
Group type: EXPERIMENTAL
Intervention: History of abdominal surgery as a predictor
Number of subjects: 1643
Study 8575676 — intervention group
Group type: EXPERIMENTAL
Intervention: Gyno-Pevaryl 150 treatment
Number of subjects: 50
Study 8575676 — intervention group
Group type: COMPARATOR
Intervention: Control group (without G-P 150 treatment)
Number of subjects: 50
Study 2234646 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose aspirin therapy
Number of subjects: 39
Study 2234646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 2234646 — intervention group
Group type: EXPERIMENTAL
Intervention: Public promotion of a healthy lifestyle
Number of subjects: 39
Study 2234646 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug therapy or research in pregnancy
Number of subjects: 39
Study 685753 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin, 1200 mg/day
Number of subjects: 585
Study 685753 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin + Sulfinpyrazone
Number of subjects: 585
Study 685753 — intervention group
Group type: COMPARATOR
Intervention: Sulfinpyrazone alone
Number of subjects: 585
Study 685753 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 585
Study 30951501 — intervention group
Group type: EXPERIMENTAL
Intervention: Hibiscus sabdariffa beverage (HSB)
Number of subjects: 6
Study 30951501 — intervention group
Group type: COMPARATOR
Intervention: Aqueous extract of H. sabdariffa (AEHS)
Number of subjects: 6
Study 28245383 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment group (hydroxyurea plus IFN‐α)
Number of subjects: 50
Study 28245383 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine treatment group (hydroxyurea)
Number of subjects: 50
Study 28245383 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 healthy persons)
Number of subjects: 50
Study 25398727 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine
Number of subjects: 0
Study 25398727 — intervention group
Group type: EXPERIMENTAL
Intervention: Lokomat
Number of subjects: 0
Study 25398727 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 0
Study 24135482 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroperitoneoscopic pyelolithotomy (RP)
Number of subjects: 44
Study 24135482 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous nephrolithotomy (PNL)
Number of subjects: 44
Study 22985776 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy plus chemotherapy (IMRT-C)
Number of subjects: 0
Study 22985776 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 0
Study 19571051 — intervention group
Group type: EXPERIMENTAL
Intervention: iBond Gluma inside (IB)
Number of subjects: 30
Study 19571051 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil S3 Bond (CS)
Number of subjects: 30
Study 19571051 — intervention group
Group type: EXPERIMENTAL
Intervention: iBond Gluma inside with an extra layer (IBB)
Number of subjects: 30
Study 19571051 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil S3 Bond with an extra layer (CSB)
Number of subjects: 30
Study 19571051 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30
Study 17672073 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesil (200 mg/day)
Number of subjects: 90
Study 17672073 — intervention group
Group type: EXPERIMENTAL
Intervention: Aponil (200 mg/day)
Number of subjects: 90